Page 66 - 84_02
P. 66
brainstem cannabinoid CB2 receptors. Science 2005; endocannabinoid system. Eur J Pharmacol 2014; 722:
310: 329–32. 134–46.
22 Ashton JC, Friberg D, Darlington CL, Smith PF. 36 Abrams DI, Guzman M. Cannabis in cancer care. Clin
Expression of the cannabinoid CB2 receptor in the rat Pharmacol Ther 2015; 97: 575–86.
cerebellum: an immunohistochemical study. Neurosci
Lett 2006; 396: 113–6. 37 Velasco G, Hernández-Tiedra S, Dávila D, Lorente M.
The use of cannabinoids as anticancer agents. Prog
23 Onaivi ES, Ishiguro H, Liu Q-R. Future perspectives: Neuropsychopharmacol Biol Psychiatry 2016; 64:
Cannabinoid CB2 receptor ligands and their 259–66.
therapeutic potential in mental diseases. In: Fattore L,
Ed. Cannabinoids in Neurologic and Mental Disease. 38 Guzmán M. Cannabinoids: potential anticancer
New York: Elsevier, 2015, pp 425–44. agents. Nat Rev Cancer 2003; 3: 745–55.
24 Chung ES, Bok E, Chung YC, Baik HH, Jin BK. 39 Chakravarti B, Ravi J, Ganju RK. Cannabinoids as
Cannabinoids prevent lipopolysaccharide-induced therapeutic agents in cancer?: current status and future
neurodegeneration in the rat substantia nigra in vivo implications. Oncotarget 2014; 5: 5852–72.
through inhibition of microglial activation and
NADPH oxidase. Brain Res 2012; 1451: 110–16. 40 Velasco G, Sánchez C, Guzmán M. Towards the use
of cannabinoids as antitumour agents. Nat Rev Cancer
25 Morales P, Gómez-Cañas M, Navarro G, et al. 2012; 12: 436–44.
Chromenopyrazole, a Versatile Cannabinoid Scaffold
with in Vivo Activity in a Model of Multiple 41 Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P,
Sclerosis. J Med Chem 2016; 59: 6753–71. Laezza C, Bifulco M. Update on the endocannabinoid
system as an anticancer target. 2011; 15: 297–308.
26 Gómez-Cañas M, Morales P, García-Toscano L, et al.
Biological characterization of PM226, a 42 Caffarel MM, Sarrió D, Palacios J, Guzmán M,
chromenoisoxazole, as a selective CB2 receptor Sánchez C. Delta9-tetrahydrocannabinol inhibits cell
agonist with neuroprotective profile. Pharmacol Res cycle progression in human breast cancer cells
2016; 110: 205–15. through Cdc2 regulation. Cancer Res 2006; 66: 6615–
21.
27 Jemal A, Bray F, Center MM, Ferlay J, Ward E,
Forman D. Global cancer statistics. CA Cancer J Clin 43 Guzmán M, Duarte MJ, Blázquez C, et al. A pilot
2011; 61: 69–90. clinical study of Delta9-tetrahydrocannabinol in
patients with recurrent glioblastoma multiforme. Br J
28 Tramèr MR, Carroll D, Campbell F, Reynolds DJ, Cancer 2006; 95: 197–203.
Moore R, McQuay HJ. Cannabinoids for control of
chemotherapy induced nausea and vomiting: 44 Asche C. Antitumour Quinones. Mini-Reviews Med
quantitative systematic review. Br Med J 2001; 323: Chem 2005; 5: 449–467.
16–21.
45 Lu J-J, Bao J-L, Wu G-S, et al. Quinones derived
29 Berry EM, Mechoulam R. Tetrahydrocannabinol and from plant secondary metabolites as anti-cancer
endocannabinoids in feeding and appetite. Pharmacol agents. Anticancer Agents Med Chem 2013; 13: 456–
Ther 2002; 95: 185–90. 63.
30 Jatoi A, Windschitl HE, Loprinzi CL, et al. 46 Alcaín FJ, Villalba JM. NQO1-directed antitumour
Dronabinol versus megestrol acetate versus quinones. Expert Opin Ther Patents 2007; 17: 649–65.
combination therapy for cancer-associated anorexia: a
North Central Cancer Treatment Group study. J Clin 47 El-Najjar N, Gali-Muhtasib H, Ketola RA, Vuorela P,
Oncol 2002; 20: 567–73. Urtti A, Vuorela H. The chemical and biological
activities of quinones: overview and implications in
31 Walsh D, Nelson KA, Mahmoud FA. Established and analytical detection. Phytochem Rev 2011; 10: 353–
potential therapeutic applications of cannabinoids in 70.
oncology. Support Care Cancer 2003; 11: 137–43.
48 O’Brien PJ. Molecular mechanisms of quinone
32 Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. cytotoxicity. Chem Biol Interact 1991; 80: 1–41.
Molecular mechanisms of cancer pain. Nat Rev
Cancer 2002; 2: 201–9. 49 Vujcic MT, Tufegdžic S, Novakovic I, Djikanovic D,
Gašic MJ, Sladic D. Studies on the interactions of
33 Campbell FA, Tramèr MR, Carroll D, Reynolds DJ, bioactive quinone avarone and its methylamino
Moore RA, McQuay HJ. Are cannabinoids an derivatives with calf thymus DNA. Int J Biol
effective and safe treatment option in the management Macromol 2013; 62: 405–410.
of pain? A qualitative systematic review. BMJ 2001;
323: 13–6. 50 Wondrak GT. Redox-directed cancer therapeutics:
molecular mechanisms and opportunities. Antioxid
34 Iversen L, Chapman V. Cannabinoids: a real prospect Redox Signal 2009; 11: 3013–69.
for pain relief? Curr Opin Pharmacol 2002; 2: 50–5.
51 Cabello CM, Bair WB, Wondrak GT. Experimental
35 Sharkey K, Darmani N, Parker L. Regulation of therapeutics: targeting the redox Achilles heel of
nausea and vomiting by cannabinoids and the cancer. Curr Opin Investig Drugs 2007; 8: 1022–37.
@Real Academia Nacional de Farmacia. Spain 52 Gehrmann M. Drug evaluation: STA-4783--enhancing
taxane efficacy by induction of Hsp70. Curr Opin
181
